Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Proprietary System Could Help Reduce Bladder Cancer Recurrence
The current standard for bladder cancer visualization, white light, is over three decades old and used in 95% of the bladder cancer surgeries The recurrence rate of bladder cancer is more than 50% due to the inability to see clear margins in the white light surgical standard for visualization Imagin Medical Inc.’s proprietary i/Blue(TM) System changes the way that surgeons visualize bladder cancer with side-by-side imaging of white and blue light pictures on one screen Blue light procedures are capable of reducing recurrence rates by 12-43% depending on the type, stage, and grade of bladder cancer The global bladder cancer…